



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# HIV MONITORING QUARTERLY REPORT **FOR FRASER HEALTH**

FIRST QUARTER 2014



BC Centre for Disease Control  
An agency of the Provincial Health Services Authority



First Nations Health Authority  
Health through wellness



fraserhealth



Interior Health  
For your whole life



island health



northern health  
the northern way of caring



How you want to be treated.



Promoting wellness. Ensuring care.



## Foreword

As part of the BC Centre for Excellence (BC-CFE) in HIV/AIDS's mandate to evaluate the outcomes of STOP HIV/AIDS programming in BC, we have developed quarterly HIV/AIDS monitoring reports. These reports provide up-to-date data on a variety of key HIV-related surveillance and treatment indicators. Selection of these indicators was achieved through a collaborative process with various Health Authority (HA) representatives. There are six reports in total, one for each HA and one for the province of BC as a whole. In addition, there is a technical report which explains how each HIV indicator is calculated. Data used in these reports come from the British Columbia Centre for Disease Control (BCCDC), MSP billings, hospitalization data from the Discharge Abstract Database, the Sunquest Laboratory database at the Provincial Public Health Microbiology and Reference Laboratory, Providence Health Care laboratory and the BC-CFE Drug Treatment Program (DTP) Database.

The objectives of these reports are to:

1. Provide timely HA-specific information on key HIV indicators which will guide and inform HIV leaders and innovators in the development of future HIV interventions and programs which will ultimately lead to decreasing the burden of HIV in BC. The indicators will reflect ongoing or past successful public health interventions and highlight areas in the HIV care spectrum which require further attention and support.
2. Highlight limitations in our current data due to incomplete or time lagged data and to develop future strategies to improve complete and timely data capture.

These reports are produced for the benefit of individual HA's. As such, we are enthusiastic about your involvement and cooperation regarding the development of these monitoring reports. Please forward your comments and queries to Irene Day, Director of Operations at the BC-CFE at [iday@cfenet.ubc.ca](mailto:iday@cfenet.ubc.ca).

## List of Indicators

Indicator 1. Testing Episodes

Indicator 2. HIV Testing Rate

Indicator 3. New HIV Diagnoses

Indicator 4. Stage of HIV Infection at Diagnosis

Indicator 5. HIV Cascade of Care

Indicator 6. Programmatic Compliance Score (PCS)

Indicator 7. New Antiretroviral Starts

Indicator 8. CD4 Cell Count at ART Initiation

Indicator 9. Active and Inactive Drug Treatment Program Participants

Indicator 10. Antiretroviral Adherence Level

Indicator 11. Resistance Testing Results by Resistance Category

Indicator 12. AIDS-Defining Illness

Indicator 13. HIV-Related Mortality

# Table of Contents

## Acknowledgements and Contributions

### BC Provincial STOP Program:

### A Note on Monitoring and Interpreting HIV Indicators

#### **Indicator 1 HIV Testing Episodes**

- Figure 1.1 HIV Test Episodes for Fraser Health, 2009 Q2–2014 Q1
- Figure 1.2 HIV Test Episodes for Fraser Health by Gender and Prenatal Status, 2009 Q2–2014 Q1
- Figure 1.3 HIV Test Episodes for Fraser Health by Age Category, 2009 Q2–2014 Q1
- Figure 1.4 Point-of-Care HIV Tests for Fraser Health, 2010 Q4–2014 Q1
- Figure 1.5 HIV Test Episodes by HSDA for Fraser Health, 2009 Q2–2014 Q1

#### **Indicator 2 HIV Testing Rates**

- Figure 2.1 Rate of HIV Testing for Fraser Health and HSDA's, 2009–2013
- Figure 2.2 Rate of HIV Testing for Fraser Health by Gender, 2009–2013
- Figure 2.3 Rate of HIV Testing for Fraser Health by Age Category, 2009–2013

#### **Indicator 3 New HIV Diagnoses**

- Figure 3.1 New HIV Diagnoses for Fraser Health, 2009 Q2–2014 Q1
- Figure 3.2 New HIV Diagnoses for Fraser Health by Gender, 2009 Q2–2014 Q1
- Figure 3.3 New HIV Diagnoses for Fraser Health by Age Category, 2009 Q2–2014 Q1
- Figure 3.4 New HIV Diagnoses for Fraser Health by Exposure Category, 2009 Q2–2013 Q3
- Figure 3.5 New HIV Diagnoses for Fraser Health by HSDA, 2009 Q2–2014 Q1

#### **Indicator 4 Stage of HIV Infection at Diagnosis**

- Table 1 Staging Classifications of Infection at Time of HIV Diagnosis Based on CDC HIV Surveillance Case Definitions
- Figure 4.1 Stage of HIV Infection at Diagnosis for Fraser Health, 2010–2013
- Figure 4.2 Stage of HIV Infection at Diagnosis for Fraser Health by Gender, 2010–2013
- Figure 4.3 Stage of HIV Infection at Diagnosis for Fraser Health by Age Category, 2010–2013
- Figure 4.4 Stage of HIV Infection at Diagnosis for Fraser Health by Exposure Category, 2010–2012

#### **Indicator 5 HIV Cascade of Care**

- Figure 5.1 Estimated Cascade of Care for Fraser Health, Year Ending 2014 Q1
- Figure 5.2 Estimated Cascade of Care for Fraser Health by Gender, Year Ending 2014 Q1

Figure 5.3	Estimated Cascade of Care for Fraser Health by Age Category, Year Ending 2014 Q1
Figure 5.4	Estimated Cascade of Care for Fraser Health by MSM Status, Year Ending 2014 Q1
Figure 5.5	Estimated Cascade of Care for Fraser Health by Age Category and MSM Status, Year Ending 2014 Q1
Figure 5.6	Estimated Cascade of Care for Fraser Health by History of IDU, Year Ending 2014 Q1
Figure 5.7	Estimated Cascade of Care for Fraser Health by HSDA, Year Ending 2014 Q1
<b>Indicator 6</b>	<b>Programmatic Compliance Score (PCS)</b>
Table 2	Probability of Mortality Based on the Programmatic Compliance Score
Figure 6.1	PCS Components for Fraser Health, 2012 Q2–2014 Q1 <ul style="list-style-type: none"> <li>First-Year CD4 Measurement</li> <li>First-Year VL measurement</li> <li>Baseline Resistance Testing</li> <li>Recommended Antiretroviral Therapy (ART)</li> <li>Baseline CD4 <math>\geq 200</math> cells/<math>\mu</math>L</li> <li>Suppression at 9 Months</li> </ul>
Figure 6.2	Historical Trends for PCS Score for Fraser Health, 2012 Q2–2014 Q1
<b>Indicator 7</b>	<b>New Antiretroviral Therapy Starts in Fraser Health</b>
Figure 7	BC-CfE Drug Treatment Program Enrollment: New Antiretroviral Participants for Fraser Health, 2012 Q2–2014 Q1
<b>Indicator 8</b>	<b>CD4 Cell Count at ART Initiation</b>
Figure 8	CD4 Cell Count at ART Initiation for Fraser Health, 2012 Q2–2014 Q1
<b>Indicator 9</b>	<b>Active and Inactive Drug Treatment Program (DTP) Participants</b>
Table 3	Distribution of People on ART in Fraser Health, 2014 Q1
Figure 9	Active and Inactive DTP Participants for Fraser Health, 2012 Q2–2014 Q1
<b>Indicator 10</b>	<b>Antiretroviral Adherence</b>
Figure 10	Distribution of Individuals by Adherence Level in 1st Year of Therapy, Based on Pharmacy Refill Compliance for Fraser Health, 2012 Q2–2014 Q1
<b>Indicator 11</b>	<b>Resistance Testing and Results</b>
Figure 11	Cumulative Resistance Testing Results by Resistance Category for Fraser Health, 2012 Q2–2014 Q1
<b>Indicator 12</b>	<b>AIDS-Defining Illness</b>
Figure 12	AIDS Case Rate and Reports for Fraser Health, 2006–2013
<b>Indicator 13</b>	<b>HIV-Related Mortality</b>
Figure 13	HIV-Related Deaths by Year for Fraser Health, 2004–2011

# Acknowledgements and Contributions



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

**British Columbia Centre for Excellence in HIV/AIDS (BC-CFE):** The BC-CFE is responsible for the conception, preparation and ongoing review of this quarterly report. The BC-CFE provides the data and outputs for Indicators 5 (Hiv Cascade of Care), 6 (Programmatic Compliance Score), 7 (New Antiretroviral Starts), 8 (CD4 Cell Count at ART Initiation), 9 (Active and Inactive Drug Treatment Program Participants), 10 (Antiretroviral Adherence Level), 11 (Resistance Testing Results by Resistance Category), 12 (AIDS-Defining Illness), and 13 (HIV-Related Mortality). The BC-CFE database provides PVL and CD4 cell count testing data, as well as ART use. All PVL measurements in BC are performed at the St Paul's Hospital virology laboratory, thus PVL data capture is 100%. An estimated 80% of all CD4 count measurements performed in the province are captured in the BC-CFE data holdings. The STOP HIV/AIDS Technical Monitoring Committee-BC-CFE is responsible for oversight of the monitoring report. Motoi Matsukura writes and compiles the monitoring report. Guillaume Colley, Dr. Viviane Lima and Nada Gataric perform analysis of Indicators 5–13. James Nakagawa is responsible for publishing and editing. This report was conceived and guided by Dr. Julio Montaner.



BC Centre for Disease Control  
An agency of the Provincial Health Services Authority

**British Columbia Centre for Disease Control (BCCDC):** The BCCDC provides the data and outputs for Indicator 1 (Hiv Testing Episodes), Indicator 2 (Hiv Testing Rate), Indicator 3 (New Hiv Diagnoses), Indicator 4 (Stage of Hiv at Diagnosis) and Indicator 12 (AIDS-Defining Illness). The BCCDC is the single provincial agency that centralizes all HIV surveillance through the Public Health Microbiology and Reference Laboratory, which does more than 90% of all HIV screening tests in BC and all confirmatory testing. Theodora Consolacion and Dr. Mark Gilbert are responsible for outputs for Indicators 1–4.

## Other Data Sources:

The above databases were supplemented with:

- (I) The BC Vital Statistics database which was used to calculate Indicator 5. The Hiv Cascade of Care and Indicator 13. HIV-Related Mortality.
- (II) Linkage and preparation of the de-identified individual-level database used for calculating Indicator 5. The Hiv Cascade of Care was facilitated by the British Columbia Ministry of Health.
- (III) The Statistics Canada database: BC and HIV-positive population counts were acquired through the statistics Canada website to calculate HIV-specific mortality rates for Indicator 13. HIV-Related Mortality.

# Membership of the STOP HIV/AIDS Technical Monitoring Committee–BC-CfE

Dr. Rolando Barrios, *Chair*, BC-CfE

Kate Heath, BC-CfE

Bohdan Nosyk, BC-CfE

Viviane Dias Lima, BC-CfE

Irene Day, BC-CfE

Dr. Mark Gilbert, BCCDC

Dr. Mel Kradjen, BCCDC

Stephanie Konrad, FHA

Joanne Nelson, FNHA

Jennifer May-Hadford, IHA

James Haggerstone, NHA

Dr. Neora Pick, PHSA

Dr. Reka Gustafson, VCHA

Melanie Rusch, VIHA



# The Seek and Treat for Optimal Prevention (STOP) HIV/AIDS BC Provincial Program: A Note on Monitoring and Interpreting HIV Indicators

The Seek and Treat for Optimal Prevention (STOP) of HIV/AIDS programme is a provincial initiative to improve HIV diagnosis and care delivery in BC through increased HIV-specific funding to all HSDA's across BC. The STOP provincial programme is an expansion of a four-year STOP pilot project which was implemented in two Health Service Delivery Areas in March 2010; the Vancouver HSDA which bears the largest burden of the HIV epidemic in the province and the Northern Interior HSDA which bears a high burden of HIV-related mortality. The STOP pilot project demonstrated the urgent need for improved efforts in early diagnosis of HIV and timely initiation of antiretroviral therapy (ART) initiation.

The expansion to a province-wide programme was announced on November 30th 2013 by the BC Ministry of Health with roll out of funding beginning on April 1st, 2013. This funding is intended to be used in the implementation and evaluation of HIV-related diagnosis and care initiatives within individual HA's. Goals of the project include: 1. A reduction in the number of new HIV infections in BC; 2. Improvements in the quality, effectiveness, and reach of HIV prevention services; 3. An increase in early diagnosis of HIV; 4. A reduction in AIDS cases and HIV-related mortality.

The goals of HA-led STOP-funded initiatives are to work toward achieving these goals. To these ends some outcome measures or indicators of progress have been drafted that should be considered in the design and implementation phases of these initiatives.

# HIV Testing Episodes and Rates

In this section, the number of HIV test episodes and point of care (POC) HIV tests conducted each quarter in BC is shown. In general terms the goal is to increase the number of tests performed and to maximize testing efficiency. Test episodes are allocated by region according to where the test is performed.

## Indicator 1. HIV Testing Episodes

Figure 1.1 HIV Test Episodes for Fraser Health, 2009 Q2–2014 Q1





Figure 1.2 HIV Test Episodes by Gender and Prenatal Status for Fraser Health, 2009 Q2–2014 Q1<sup>1</sup>



<sup>1</sup> NB: Testing does not include point of care tests.

Figure 1.3 HIV Test Episodes by Age Category for Fraser Health, 2009 Q2–2014 Q1 <sup>1,2</sup>





Figure 1.4 Point-of-Care HIV Tests for Fraser Health, 2010 Q4–2014 Q1




<sup>2</sup> Data Source: The BC Public Health Microbiology and Reference Laboratory (BCPHMRL) courtesy of the BC Centre for Disease Control (BCCDC).

**Limitations:**

- 1 Repeat tests in individuals who test using various identifiers may not be identified and these individuals may be counted more than once.
- 2 POC testing data is available from the fourth quarter of 2010 and onwards.

Figure 1.5 HIV Test Episodes for Fraser Health, 2009 Q2–2014 Q1





## Indicator 2. HIV Testing Rates

Figure 2.1 Rate of HIV Testing for Fraser Health and HSDAs, 2009–2013 <sup>1</sup>




Figure 2.2 Rate of HIV Testing by Gender for Fraser Health, 2009–2013 <sup>1</sup>





Figure 2.3 Rate of HIV Testing by Age Category for Fraser Health, 2009–2013 <sup>1</sup>




<sup>1</sup> NB: Testing does not include point of care tests.

# New HIV Diagnoses

Trends in HIV diagnoses by gender and exposure category are described. Interpreting HIV diagnoses must be done with consideration that trends are influenced by both changes in testing rate as well as changes in transmission rates. It is important to note that new HIV diagnoses cases and rates are not synonymous with HIV incidence as a person may have become infected with HIV long before they tested positive for HIV. However, as there is no reliable method for measuring HIV incidence we follow trends in HIV diagnoses.


## Indicator 3. New HIV Diagnoses

Figure 3.1 New HIV Diagnoses for Fraser Health, 2009 Q2–2014 Q1<sup>3</sup>



Fraser Health  
By Client Residence  
By Provider Address

Figure 3.2 New HIV Diagnoses for Fraser Health by Gender, 2009 Q2–2014 Q1<sup>3</sup>



<sup>3</sup> Data Source: BCCDC. "By Provider Address" is graphed as dashed line in same colour.



Figure 3.3 New HIV Diagnoses for Fraser Health by Age Category, 2009 Q2–2014 Q1<sup>3</sup>




Figure 3.4 New HIV Diagnoses for Fraser Health by Exposure Category, 2009 Q2–2013 Q3<sup>3,4</sup>





Figure 3.5 New HIV Diagnoses for Fraser Health by HSDA, 2009 Q2–2014 Q1<sup>3</sup>



<sup>3</sup> Data Source: BCCDC. "By Provider Address" is graphed as dashed line in same colour.

<sup>4</sup> MSM=men who have sex with men; IDU= injection drug user; HET=heterosexual. NIR=No identified risk/exposure.

# Stage of HIV infection at diagnosis

Classification of stage of HIV infection, in the absence of information regarding recent testing history, is reliant on clinical information available at the time of diagnosis, including first CD4+ cell count, laboratory results suggestive of acute HIV infection, and clinical presentation with an AIDS-defining illness (Table 1). The benefits of Treatment as Prevention (TasP) are maximized when antiretroviral therapy (ART) is initiated at high CD4 cell counts. Accordingly, it is preferable that individuals newly diagnosed with HIV be in the early stages of HIV infection (stage 0 or 1) to allow for early ART initiation.

*N.B. Interpretation of stage of HIV infection at diagnosis should proceed with caution. Early increases in diagnosis at late stage (i.e., low CD4 counts) may represent a “catching up” of previously missed long term infected individuals rather than a trend toward diagnosis at later stage of infection.*

## Indicator 4. Stage of HIV Infection at Diagnosis

Table 1 Staging Classifications of Infection at Time of HIV Diagnosis Based on CDC HIV Surveillance Case Definitions

Stage	Criteria		
0	Laboratory criteria met for acute HIV infection, or previous negative or indeterminate HIV test within 180 days of first confirmed positive HIV test.		
1	Stage 0 not met	CD4 ≥500	No AIDS case report
2a		CD4 350–499	
2b		CD4 200–349	
3		( CD4 <200	AIDS case report )
Unknown		No available CD4	No AIDS case report

Figure 4.1 Stage of HIV Infection at Diagnosis for Fraser Health, 2010–2013 <sup>5</sup>





Figure 4.2 Stage of HIV Infection at Diagnosis by Gender for Fraser Health, 2010–2013 <sup>5</sup>



	Fraser Health				Female				Male			
	2010	2011	2012	2013	2010	2011	2012	2013	2010	2011	2012	2013
Stage 0	8	10	3	6	2	1	0	0	6	9	3	6
Stage 1	14	8	6	9	5	2	1	4	9	6	5	5
Stage 2a	5	2	5	6	1	1	3	1	4	1	2	5
Stage 2b	9	7	6	10	2	2	1	1	7	5	5	9
Stage 3	17	21	9	15	6	3	2	1	11	18	7	14
Unknown	2	1	2	4	0	1	0	0	2	0	2	4
Total (n=)	55	49	31	50	16	10	7	7	39	39	24	43

5 Data Source: BCCDC

Figure 4.3 Stage of HIV Infection at Diagnosis by Age Category for Fraser Health, 2010–2013 <sup>5</sup>





Figure 4.4 Stage of HIV Infection at Diagnosis by Exposure Category for Fraser Health, 2010–2012 <sup>5,6</sup>



6 MSM=men who have sex with men; IDU= injection drug user; HET=heterosexual. NIR=No identified risk/exposure.

# Indicator 5. HIV Cascade of Care

The success of seek, test, treat and retain (STTR) strategies like STOP is reliant on early diagnosis of HIV, linking newly diagnosed HIV-positive persons with ongoing care, retaining persons in HIV-care; initiating ART based on best evidenced practices and maintaining optimal ART adherence to ensure a suppressed viral load. These stages of HIV-care can be summarized as: 1. HIV diagnosis, 2. Linkage to HIV care, 3. Retention in HIV care, 4. On ART and 5. Achieving a suppressed VL; collectively, they are referred to as the cascade of care. Leakage between any of these stages of HIV-care means a reduction in the potential of ART as a benefit to the HIV-positive individual and as an HIV transmission prevention method on a population level. Thus, when interpreting trends in the cascade of care, we strive to see increases along each step of the cascade of care (ie. reduced attrition) with the ultimate goal being 100% within each stage of the cascade. Monitoring the Cascade of Care provides a picture as to where deficiencies lie in the delivery and uptake of HIV-care. In this section we present the cascade of care for the year 2012 in BC overall and stratified by sex and age for each Health Authority.

Figure 5.1      Estimated Cascade of Care for Fraser Health, Year Ending 2014 Q1 <sup>7</sup>






Figure 5.2      Estimated Cascade of Care for Fraser Health by Gender, Year Ending 2014 Q1 <sup>8</sup>




7,8 Data is for the period 2013 Q2–2014 Q1.  
 Data Sources:  
 1 British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).  
 2 Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).  
 Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.  
 NB: Transgender has been assigned to their biological sex.

Figure 5.3      Estimated Cascade of Care for Fraser Health by Age Category, Year Ending 2014 Q1 <sup>9</sup>



<sup>9</sup> Data is for the period 2013 Q2–2014 Q1.  
Data Sources:  
1 British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).  
2 Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).  
Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider.  
If the most recent HA of residence is not updated then the designated HA may be incorrect.

Figure 5.4 Estimated Cascade of Care for Fraser Health by MSM Status, Year Ending 2014 Q1 <sup>10</sup>




<sup>10</sup> Data is for the period 2013 Q2–2014 Q1.

Data Sources:

- 1 British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).
- 2 Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).

Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.

Figure 5.5 Estimated Cascade of Care for Fraser Health by Age Category and MSM Status, Year Ending 2014 Q1 <sup>11</sup>




<sup>11</sup> Data is for the period 2013 Q2–2014 Q1.

Data Sources:

- 1 British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).
- 2 Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).

Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.

Figure 5.6 Estimated Cascade of Care for Fraser Health by History of IDU, Year Ending 2014 Q1 <sup>12</sup>



<sup>12</sup> Data is for the period 2013 Q2–2014 Q1.


Data Sources:

- 1 British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).
- 2 Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).

Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.



Figure 5.7 Estimated Cascade of Care for Fraser Health by HSDA, Year Ending 2014 Q1 <sup>13</sup>



<sup>13</sup> Data is for the period 2013 Q2–2014 Q1.

Data Sources:

- 1 British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).
- 2 Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).

Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.

## Indicator 6. The Programmatic Compliance Score (PCS)

The Programmatic Compliance Score (PCS) is a summary measure of risk of future death, immunologic failure and virologic failure from all causes for people who are starting ART for the first time. It is composed of patient- and physician-driven effects. PCS scores range from 0–6 with higher scores indicative of poorer health outcomes and greater risk of death. Table 1 provides mortality, immunologic failure and virologic failure probabilities for given PCS scores. We interpret an individual with a  $PCS \geq 4$  as being 22 times more likely to die, almost 10 times more likely to have immunologic failure and nearly 4 times as likely to demonstrate virologic failure compared to those individuals with a PCS score of 0. A detailed description of how the PCS score is calculated and its validation can be found in the technical report. In short, PCS scores are calculated by summing the results (yes=1, no=0) of six un-weighted non-performance indicators based on IAS–USA treatment guidelines:

1. having <3 CD4 cell count tests in the first year after starting antiretroviral therapy (ART);
2. having <3 plasma viral load (VL) tests in the first year after starting ART;
3. not having drug resistance testing done prior to starting ART;
4. starting on a non-recommended ART regimen;
5. starting therapy with  $CD4 < 200$  cells/ $\mu$ L; and
6. not achieving viral suppression within 9 months since ART initiation.

In this section we provide PCS scores and their components over time for the province of BC. A decline to 0%, (i.e., all individuals having a score of 0) is the eventual goal.

Table 2. The Probability of Mortality, Immunologic Failure and Virologic Failure based on the Programmatic Compliance Score

Programmatic Compliance Score	Mortality Risk Ratio (95% Confidence Interval)	Immunologic Failure Risk Ratio (95% CI)	Virologic Failure Risk Ratio (95% CI)
0 (Best score)	1 (–)	1 (–)	1 (–)
1	3.81 (1.73–8.42)	1.39 (1.04–1.85)	1.32 (1.05–1.67)
2	7.97 (3.70–17.18)	2.17 (1.54–3.04)	1.86 (1.46–2.38)
3	11.51 (5.28–25.08)	2.93 (1.89–4.54)	2.98 (2.16–4.11)
4 or more (Worst score)	22.37 (10.46–47.84)	9.71 (5.72–16.47)	3.80 (2.52–5.73)

Reference: Lima VD, Le A, Nosyk B, Barrios R, Yip B, et al. (2012) Development and Validation of a Composite Programmatic Assessment Tool for HIV Therapy. *PLoS ONE* 7(11): e47859. doi:10.1371/journal.pone.0047859

Figure 6.1 PCS Components for Fraser Health, 2012 Q2–2013 Q4 <sup>14</sup>





Figure 6.2 Historical Trends for PCS Score for Fraser Health, 2012 Q2–2014 Q1 <sup>14,15</sup>



<sup>14</sup> Data Source: British Columbia Centre for Excellence Drug Treatment Program (DTP) Database. Limitations: CD4 cell count capture is approximately 80%. Due to improvements in the automated system, some changes in data representation are expected compared to previous reports.


<sup>15</sup> Each quarter's data is calculated as the sum of the 4 quarters leading up to it. e.g. 2013 Q1 is calculated from 2012 Q2 – 2013 Q1. NB: A score of 0 is the best score and a score of 4 or more is the worst score.

# Antiretroviral Uptake

In this section we present trends in ART uptake, the number and proportion of new HIV treatment initiations and the number of active and inactive DTP participants. Trends in ART uptake should be interpreted under the consideration of changing BC HIV treatment guidelines. BC HIV treatment guidelines are updated regularly by the BC-CFE Therapeutic Guidelines Committee and reflect those of the International AIDS Society. Most recent changes were made in 2012 and HIV treatment is now recommended for all HIV-positive adults regardless of CD4 cell count; as evidence demonstrates that early initiation of HIV treatment maximizes both the individual's health outcomes as well as the potential of ART as a form of HIV transmission prevention at a population level. As such, trends in the number and proportion of persons on ART and new ART starts (in both naïve and experienced persons) are expected to increase over time at higher CD4 cell counts.


## Indicator 7. New Antiretroviral Therapy Starts in Fraser Health

Figure 7 BC-CfE Drug Treatment Program Enrollment: New ART Participants in Fraser Health, 2012 Q2–2014 Q1 <sup>16</sup>



## Indicator 8. CD4 Cell Count at ART Initiation

Figure 8 CD4 Cell Count at ART Initiation of ART-Naïve DTP Participants in Fraser Health, 2012 Q2–2014 Q1 <sup>17</sup>



<sup>16</sup> Data Source: Drug Treatment Program Database

Limitation: DTP participants are designated to an HA based on most current residence provided by the participant.

<sup>17</sup> Data Source: Drug Treatment Program Database


Limitations: CD4 cell count data is approximately 80% complete.

## Indicator 9. Active and Inactive DTP Participants

Table 3. Distribution of People on ART for Fraser Health, 2014 Q1 <sup>18</sup>

Age	< 30	64
	30–39	264
	40–49	534
	≥ 50	725
Gender	Male	1230
	Female	357
Exposure	MSM	457
	IDU	443
Total		1587

Figure 9 Active and Inactive DTP Participants in Fraser Health, 2012 Q2–2014 Q1 <sup>19</sup>



<sup>18</sup> Data Source: Drug Treatment Program Database

Limitation: DTP participants are designated to an HA based on most current residence provided by the participant.

Definitions:

'On antiretroviral therapy' defined as being on treatment in the current quarter

'Unknown/not stated' defined as being on treatment in the current quarter, and city of residence unknown

<sup>19</sup> Active DTP participants: are those who are prescribed one or more drugs in the last six months.


Inactive DTP Participants: Persons no longer prescribed drugs through the HIV/AIDS Drug Treatment Program in the last quarter.

# Antiretroviral Adherence Level

In this section we present trends in prescription refill adherence levels for individuals in their first year of treatment. Given that the benefits of ART are compromised in the presence of imperfect ART adherence, we expect to see the proportion of persons on ART achieving **near perfect adherence** (ie.  $\geq 95\%$ ) to increase with time. Furthermore, it is important that trends in the proportion of ART users achieving prescription refill adherence of  $\geq 95\%$  keep pace with new ART starts and increase among those continuing on ART.

## Indicator 10. Antiretroviral Adherence


Figure 10 Distribution of Individuals by Adherence Level in 1st Year of Therapy, Based on Pharmacy Refill Compliance for Fraser Health, 2012 Q2–2014 Q1 <sup>20</sup>



<sup>20</sup> Data Source: Drug Treatment Program Database  
Limitation: Prescription refill adherence is used as a proxy for patient adherence.

# Indicator 11. Resistance Testing and Results

In this section, we present trends in cumulative resistance testing by resistance category: **Suppressed** (where a DTP participant's viral load is too low to be genotyped); **Wild Type** (where no HIV treatment resistances were discovered), **Never Genotyped**, and Resistances to **one**, **two** or **three** HIV treatment classes. Resistance testing prior to ART initiation is recommended in the BC HIV treatment primary care guidelines. Thus, it is expected that trends over time should find all persons enrolled in the DTP to have been genotyped. Trends over time should also show an increase in the proportion of DTP participants achieving a suppressed status and an increase in resistance testing should not lead to an increase in the number of ART resistances occurring.




<sup>21</sup> Data Source: Drug Treatment Program Database

Limitation: DTP participants are designated to an HA based on most current residence provided by the participant.

## Indicator 12. AIDS-Defining Illness

Improvements in ART and the expansion of ART province-wide has led to very low numbers of recorded AIDS cases across BC. However, interpreting trends in AIDS cases is challenging as AIDS reporting is passive in BC and it is likely that they are under reported across all Health Authorities. In addition to under reporting, methods of reporting AIDS cases are inconsistent across HA's and do not truly reflect the current reality of new AIDS diagnoses. Efforts will need to be made to improve under and inconsistent reporting of AIDS cases across all HA's. The table below shows AIDS cases using three definitions. First, AIDS cases were defined as the number of physician-reported AIDS defining illness (ADI) in a given year. AIDS case reporting is a passive process and physicians can voluntarily report AIDS cases to the BCCDC or DTP. As such, we have plotted both **BCCDC reports** and **DTP reported AIDS cases**. We also show the proportion of persons **initiating ART with a CD4<200 cells/μL**.

Figure 12 AIDS Case Rate and Reports for Fraser Health, 2006–2013<sup>22</sup>




<sup>22</sup> Data Source: DTP AIDS cases are obtained from the Drug Treatment Program Database; BCCDC AIDS cases are obtained from the BC-CDC; CD4<200 at ART initiation data came from the DTP database.

*Limitation:* AIDS case reporting was investigated using 3 definitions: First, using AIDS cases reported in AIDS case report forms from the DTP; Second, using AIDS cases reported via the BCCDC and third, using a CD4 cell count of <200 cells/μL at time of ART initiation using DTP data. AIDS case reporting is passive in BC, thus; AIDS case reporting is not well captured. The DTP sends out AIDS reporting forms to physicians annually. The BCCDC uses DTP AIDS case reports as well as physician AIDS case reports made directly to the BCCDC. Interpreting AIDS case reports should be done with these limitations in mind. AIDS data is updated annually as very few AIDS cases reports are reported in general and trends would be difficult to notice if reported quarterly.



### Indicator 13. HIV-Related Mortality

Evidence indicates that individuals who initiate treatment with recommended ART in a timely fashion may live near normal lifespans. Excess mortality among HIV positive persons is, therefore, an important measure of HIV care with a goal of minimizing HIV-related mortality in British Columbia.



<sup>23</sup> Data Source: BC Vital Statistics

*Limitation:*

1. DTP participants are designated to an HA based on most current residence provided by the participant.
2. Mortality data is updated annually.
3. The most recent available data was used.

# Appendices

Indicator 1: <b>Test Episodes (thousands)</b>		2009			2010			2011				2012				2013				2014	
		Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1
Fraser Health		12.4	12.3	11.6	13.0	12.3	12.6	12.5	13.1	12.2	13.0	13.0	14.4	14.2	15.1	15.6	17.9	18.4	18.2	17.4	18.4
Gender	Female	7.9	7.9	7.6	8.5	7.8	8.1	8.1	8.4	7.9	8.3	8.4	9.1	9.0	9.6	9.7	11.0	11.0	11.1	10.5	11.0
	Male	4.4	4.4	3.9	4.5	4.4	4.4	4.4	4.7	4.3	4.7	4.6	5.3	5.1	5.5	5.7	6.6	7.1	6.9	6.7	7.1
	Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Female (Prenatal)		4.0	3.9	4.0	4.2	3.9	4.1	4.2	4.4	4.0	3.9	4.1	4.4	4.0	4.1	4.0	4.4	4.1	4.1	4.1	4.3
Female (Non-prenatal)		4.0	4.0	3.6	4.2	4.0	4.0	3.9	4.0	3.9	4.3	4.3	4.7	4.9	5.4	5.7	6.6	7.0	7.0	6.4	6.7
Age	< 30	5.2	5.2	4.9	5.1	5.0	5.3	5.3	5.1	4.9	5.4	5.3	5.4	5.2	5.7	5.5	5.8	5.9	6.2	5.9	5.6
	30–39	4.1	4.1	3.9	4.6	4.2	4.2	4.1	4.7	4.2	4.4	4.3	5.0	4.8	4.9	4.8	5.8	5.6	5.5	5.4	6.0
	40–49	1.7	1.7	1.6	1.9	1.7	1.7	1.7	1.9	1.7	1.8	1.8	2.0	2.0	2.0	2.3	2.7	2.8	2.6	2.4	2.7
	≥ 50	1.3	1.3	1.2	1.5	1.3	1.3	1.3	1.5	1.3	1.4	1.6	2.0	2.1	2.4	2.8	3.4	3.9	3.7	3.4	3.9
POC HIV Tests (not in thousands)								0	12	37	57	24	54	121	31	157	274	170	167	277	224
Fraser East		2.2	2.2	2.0	2.2	2.1	2.1	2.0	2.2	2.0	2.1	2.0	2.3	2.2	2.4	2.3	2.5	2.5	2.5	2.5	2.7
Fraser North		5.5	5.6	5.2	6.0	5.6	5.6	5.6	5.7	5.4	6.1	6.0	6.7	6.4	6.7	7.0	8.5	8.7	8.4	8.1	8.5
Fraser South		4.6	4.6	4.3	4.8	4.6	4.9	4.8	5.2	4.8	4.9	5.0	5.4	5.5	6.0	6.3	7.0	7.1	7.2	6.8	7.1

Indicator 2: **Rate of HIV Testing per 100,000**

		2009	2010	2011	2012	2013
Fraser Health		3386.7	3383.1	3438.2	3893.6	4262.7
Fraser East		3250.3	3140.6	3090.9	3335.8	3431.5
Fraser North		3755.0	3730.9	3829.4	4474.8	5219.1
Fraser South		3125.9	3182.6	3243.4	3620.7	3781.5
Gender	Female	4371.1	4352.3	4385.9	4868.1	5215.1
	Male	2384.2	2393.8	2472.0	2897.5	3287.3
Age	< 30	3571.9	3525.3	3524.9	3728.6	3729.2
	30–39	8525.8	8686.1	8871.3	9500.4	9665.5
	40–49	2996.2	2980.6	3083.9	3641.9	4258.7
	≥ 50	1144.4	1193.6	1310.2	1979.1	2738.0

		2009		2010			2011				2012				2013				2014		
Indicator 3: New HIV Diagnoses		Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1
Fraser Health	By Client Residence	27	21	12	17	19	19	17	12	18	15	9	11	10	10	14	8	15	24	21	16
	By Provider Address	17	17	7	14	15	13	15	10	20	9	8	10	5	7	8	9	9	14	16	12
Gender	Female	6	9	4	6	8	3	5	1	5	4	1	0	3	2	3	1	3	2	4	6
	Male	21	12	8	11	11	16	12	11	13	11	8	11	7	8	11	7	12	22	17	10
Age	< 30	2	2	5	3	5	9	1	1	3	3	3	3	1	1	2	1	3	5	6	4
	30–39	12	7	3	6	2	2	6	3	9	3	1	1	3	2	2	3	4	8	7	5
	40–49	7	6	3	6	6	5	5	2	5	4	4	3	2	5	4	2	4	6	5	3
	≥ 50	6	6	1	2	6	3	5	6	1	5	1	4	4	2	6	2	4	5	3	4
Exposure	MSM	11	5	3	4	3	11	4	7	5	8	4	6	5	6	5	6	8	10	–	–
	IDU	3	5	2	2	4	3	2	1	4	0	0	4	0	0	1	1	1	2	–	–
	HET	11	9	6	9	10	3	8	3	7	7	5	1	4	4	6	1	3	9	–	–
	Other	0	1	1	2	0	1	1	1	2	0	0	0	0	0	1	0	1	3	–	–
	NIR/Unknown	2	1	0	0	2	1	2	0	0	0	0	0	1	0	1	0	2	0	–	–
Fraser East	By Client Residence	3	4	1	2	1	2	2	4	4	2	5	2	2	1	1	0	0	3	1	2
	By Provider Address	3	3	1	4	1	1	1	4	4	2	2	2	0	1	0	0	0	2	1	2
Fraser North	By Client Residence	13	7	8	7	6	6	6	6	6	7	4	3	6	5	6	6	9	15	10	9
	By Provider Address	8	9	3	5	5	2	6	3	7	4	5	3	4	4	2	7	5	8	10	7
Fraser South	By Client Residence	11	10	3	8	12	11	9	2	8	6	0	6	2	4	7	2	6	6	10	5
	By Provider Address	6	5	3	5	9	10	8	3	9	3	1	5	1	2	6	2	4	4	5	3

**Indicator 4: Stage of HIV Infection at Baseline**

	Fraser Health				Female				Male				< 30 years				30–39 years				40–49 years			
	'10	'11	'12	'13	'10	'11	'12	'13	'10	'11	'12	'13	'10	'11	'12	'13	'10	'11	'12	'13	'10	'11	'12	'13
Stage 0	8	10	3	6	2	1	0	0	6	9	3	6	5	4	0	4	0	2	1	0	3	2	1	1
Stage 1	14	8	6	9	5	2	1	4	9	6	5	5	8	1	1	3	1	5	0	2	5	1	4	1
Stage 2a	5	2	5	6	1	1	3	1	4	1	2	5	3	0	0	2	0	2	1	2	1	0	1	2
Stage 2b	9	7	6	10	2	2	1	1	7	5	5	9	1	1	2	3	4	1	1	0	1	1	1	3
Stage 3	17	21	9	15	6	3	2	1	11	18	7	14	0	0	0	1	2	5	3	3	10	11	3	6
Unknown	2	1	2	4	0	1	0	0	2	0	2	4	1	1	1	0	0	0	0	2	1	0	1	2
Total	55	49	31	50	16	10	7	7	39	39	24	43	18	7	4	13	7	15	6	9	21	15	11	15

	≥ 50 years				MSM			IDU			Heterosexual			Other Exposure			NIR/Unknown		
	'10	'11	'12	'13	2010	2011	2012	2010	2011	2012	2010	2011	2012	2010	2011	2012	2010	2011	2012
Stage 0	0	2	1	1	4	6	2	2	1	0	2	3	1	0	0	0	0	0	0
Stage 1	0	1	1	3	5	3	2	2	1	0	7	4	3	0	0	1	0	0	0
Stage 2a	1	0	3	0	2	1	2	2	0	0	1	0	3	0	1	0	0	0	0
Stage 2b	3	4	2	4	3	2	2	1	1	1	4	4	3	1	0	0	0	0	0
Stage 3	5	5	3	5	5	8	2	2	2	3	6	10	4	3	1	0	1	0	0
Unknown	0	0	0	0	1	0	1	0	0	0	1	1	0	0	0	0	0	0	1
Total	9	12	10	13	20	20	11	9	5	4	21	22	14	4	2	1	1	0	1

Indicator 5: HIV Cascade of Care		DIAGNOSED		LINKED		RETAINED		ON ART		ADHERENT		SUPPRESSED	
Fraser Health		1885		1802		1673		1559		1429		1173	
Age Category	< 30	112		86		83		73		60		45	
	30–39	290		282		260		231		204		165	
	40–49	617		595		553		511		464		375	
	≥ 50	867		839		778		744		701		588	
Age Category and MSM Status	MSM	< 30		20		19		19		18		15	
		30–39		49		48		46		42		32	
		40–49		129		125		115		106		89	
		≥ 50		299		292		288		276		232	
	Non-MSM	< 30		13		13		12		10		6	
		30–39		120		116		108		93		63	
		40–49		269		261		245		224		156	
		≥ 50		308		300		281		269		197	
	Unknown	< 30		79		54		50		45		27	
		30–39		121		118		105		96		70	
		40–49		218		209		184		172		130	
		≥ 50		260		248		209		199		159	
Gender	Male	1438		1382		1291		1204		1133		932	
	Female	447		420		383		355		296		241	
Injection Drug Use	IDU	517		501		482		445		387		291	
	Non-IDU	975		950		914		861		819		706	
	Unknown	393		351		277		253		223		176	
MSM Status	MSM	497		484		478		451		432		365	
	Non-MSM	710		689		647		596		530		422	
	Unknown	678		629		549		512		467		386	
Health Authority	Fraser East	301		288		245		232		207		154	
	Fraser North	845		803		740		683		631		519	
	Fraser South	741		715		688		644		591		500	

**Indicator 6: Programmatic Compliance Score (PCS)**

	2012 Q2	Q3	Q4	2013 Q1	Q2	Q3	Q4	2014 Q1
< 3 CD4 Tests	19.6%	23.5%	21.7%	20.4%	16.0%	15.7%	18.3%	20.2%
< 3 Viral Load Tests	5.2%	4.9%	4.7%	6.8%	5.7%	6.7%	6.5%	3.2%
No Baseline Genotype	4.1%	3.9%	3.8%	7.8%	6.6%	7.9%	8.6%	4.3%
Baseline CD4 < 200 cells/μL	30.9%	31.4%	30.2%	29.1%	25.5%	19.1%	19.4%	19.1%
Non-Recommended ART	6.2%	5.9%	3.8%	2.9%	3.8%	6.7%	9.7%	10.6%
Non Viral suppression at 9 Mo.	36.1%	32.4%	29.2%	25.2%	26.4%	24.7%	22.6%	24.5%
PCS Score: 0	41	44	48	52	57	49	47	44
PCS Score: 1	29	28	28	21	20	20	26	31
PCS Score: 2	13	16	20	19	21	12	11	13
PCS Score: 3	12	12	9	9	6	5	6	4
PCS Score: 4 or more	2	2	1	2	2	3	3	2
<b>Total (n=)</b>	<b>97</b>	<b>102</b>	<b>106</b>	<b>103</b>	<b>106</b>	<b>89</b>	<b>93</b>	<b>94</b>

**Indicator 7: New DTP ARV Participants**

First Starts	24	21	25	23	17	29	20	31
Experienced Starts	23	29	28	20	39	24	37	21

**Indicator 8: CD4 Cell Count at ART Initiation for ARV-Naïve DTP Participants**

CD4 ≥ 500	7	6	10	7	7	4	10	9
CD4 350–499	10	5	7	9	2	3	5	4
CD4 200–349	3	2	2	4	5	8	4	10
CD4 50–199	1	6	3	2	2	8	0	3
CD4 < 50	3	2	3	1	1	6	0	4
<i>CD4 Median (cells/μL)</i>	<i>425</i>	<i>380</i>	<i>460</i>	<i>420</i>	<i>370</i>	<i>202</i>	<i>500</i>	<i>297</i>
<b>Total (n=)</b>	<b>24</b>	<b>21</b>	<b>25</b>	<b>23</b>	<b>17</b>	<b>29</b>	<b>19</b>	<b>30</b>

**Indicator 9: Active and Inactive DTP Participants**

Active DTP Participants	1407	1440	1469	1473	1520	1543	1570	1587
Inactive DTP Participants	226	232	230	245	228	232	229	237

**Indicator 10: Antiretroviral Adherence**

≥ 95%	20	30	12	18	13	15	17	19
80% to < 95%	7	4	6	9	7	6	4	5
40% to < 80%	1	3	4	0	5	3	5	2
< 40%	0	0	0	0	0	0	2	0
<b>Total (n=)</b>	<b>28</b>	<b>37</b>	<b>22</b>	<b>27</b>	<b>25</b>	<b>24</b>	<b>28</b>	<b>26</b>

**Indicator 11: Resistance Testing and Results**

Suppressed	922	949	920	1008	1001	1040	1018	1122
Wild Type	208	202	228	202	203	203	173	159
Never Genotyped	15	28	22	17	22	18	19	15
1-Class	41	36	27	27	39	35	43	29
2-Class	8	5	8	6	8	5	8	2
3-Class	1	1	2	2	3	1	1	1
<b>Total (n=)</b>	<b>1195</b>	<b>1221</b>	<b>1207</b>	<b>1262</b>	<b>1276</b>	<b>1302</b>	<b>1262</b>	<b>1328</b>

**Indicator 12: AIDS-Defining Illness**

	2006	2007	2008	2009	2010	2011	2012	2013
CD4 < 200 at Cases	47	38	52	31	33	33	25	19
ART initiation <i>Rate per 100,000</i>	<i>3.2</i>	<i>2.5</i>	<i>3.4</i>	<i>2.0</i>	<i>2.1</i>	<i>2.0</i>	<i>1.5</i>	<i>1.1</i>
AIDS Cases Cases	26	22	26	12	22	19	9	9
(DTP Reports) <i>Rate per 100,000</i>	<i>1.8</i>	<i>1.5</i>	<i>1.7</i>	<i>0.8</i>	<i>1.4</i>	<i>1.2</i>	<i>0.5</i>	<i>0.5</i>
AIDS Cases Cases	28	25	30	21	28	22	9	–
(BCCDC Reports) <i>Rate per 100,000</i>	<i>1.9</i>	<i>1.7</i>	<i>1.9</i>	<i>1.3</i>	<i>1.7</i>	<i>1.3</i>	<i>0.5</i>	<i>–</i>

**Indicator 13: HIV-Related Mortality**

	2004	2005	2006	2007	2008	2009	2010	2011
Fraser Health	18	26	23	21	14	10	18	13
Per 100 HIV+ Population	0.88	1.25	1.09	0.97	0.63	0.44	0.78	0.56
Per 100,000 Population	1.25	1.77	1.54	1.38	0.91	0.64	1.12	0.80